A selective small-molecule agonist of G protein-gated inwardly-rectifying potassium channels reduces epileptiform activity in mouse models of tumor-associated and provoked seizures
Rifkin R, Wu X, Pereira B, Gill B, Merricks E, Michalak A, Goldberg A, Humala N, Dovas A, Rai G, McKhann G, Slesinger P, Canoll P, Schevon C. A selective small-molecule agonist of G protein-gated inwardly-rectifying potassium channels reduces epileptiform activity in mouse models of tumor-associated and provoked seizures. Neuropharmacology 2024, 265: 110259. PMID: 39662702, PMCID: PMC11726401, DOI: 10.1016/j.neuropharm.2024.110259.Peer-Reviewed Original ResearchConceptsMouse modelInwardly-rectifying potassium channelRegulation of neuronal excitabilityMouse models of tumorsSeizure-like activityGIRK channelsNeuronal excitabilityModels of tumorsPeritumoral regionEpileptiform activityTumor-associatedTumor progressionAntiseizure medicationsPotassium channelsChronic epilepsyFocal seizuresAnimal modelsTumorBrain tumorsGIRKInadequate treatmentGlioma cellsMiceSeizuresChemoconvulsant modelsTertiary Lymphoid Structures and Immunotherapy: Challenges and Opportunities
Ruddle N. Tertiary Lymphoid Structures and Immunotherapy: Challenges and Opportunities. Methods In Molecular Biology 2024, 2864: 299-312. PMID: 39527229, DOI: 10.1007/978-1-0716-4184-2_16.Peer-Reviewed Original ResearchConceptsImmune-related adverse eventsImmune checkpoint inhibitorsTertiary lymphoid structuresSecondary lymphoid organsTA-TLSSusceptibility to immune-related adverse eventsAssociated with favorable clinical outcomesPositive response to immunotherapyResponse to immunotherapyFavorable clinical outcomesCellular compositionVascular growth factorsAccumulation of lymphoid cellsCheckpoint inhibitorsLymphoid neogenesisLymphoid structuresProcess of lymphoid neogenesisClinical outcomesAdenovirus vectorLymphoid cellsTumor-associatedAdverse eventsTumor environmentOrgan rejectionChronic inflammation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply